Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 10/20 | 0.59 |
| ▸ | LCK | P06239 | 1/20 | 0.58 |
| ▸ | AKT2 | P31751 | 2/20 | 0.56 |
| ▸ | GSK3B | P49841 | 2/20 | 0.56 |
| ▸ | KIT | P10721 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.55 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.54 |
| ▸ | ATR | Q13535 | 1/20 | 0.52 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 3/20 | 0.51 |
| ▸ | JAK1 | P23458 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3961817 | 0.88 | JAK3 (0.69) | JAK3LCKAKT2GSK3BKIT | |
| SCHEMBL3959598 | 0.87 | LCK (0.70) | JAK3LCKAKT2GSK3BKIT | |
| SCHEMBL3952874 | 0.79 | JAK3 (0.75) | JAK3LCKAKT2GSK3BKIT | |
| SCHEMBL31732396 | 0.78 | JAK3 (0.63) | JAK3LCKAKT2GSK3BKIT | |
| SCHEMBL3953429 | 0.78 | JAK3 (0.65) | JAK3LCKAKT2GSK3BKIT | |
| SCHEMBL3539476 | 0.76 | JAK3 (0.60) | JAK3LCKAKT2GSK3BKIT | |
| SCHEMBL31050016 | 0.76 | AKT2 (0.63) | JAK3LCKAKT2GSK3BKIT | |
| SCHEMBL1050141 | 0.76 | AKT2 (0.63) | JAK3LCKAKT2GSK3BKIT | |
| SCHEMBL7843438 | 0.74 | HTR2C (0.53) | JAK3LCKAKT2GSK3BKIT | |
| SCHEMBL4053733 | 0.74 | JAK3 (0.67) | JAK3LCKAKT2GSK3BKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1087970-B1 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PROD INC (US) | 2004-04-28 | — | — | EP | claimed |
| US-20030212273-A1 | Pyrrolo [2,3-D] pyrimidine compounds | PFIZER INC. | 2003-11-13 | — | — | US | claimed |
| US-20020019526-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2002-02-14 | — | — | US | claimed |
| CN-1305480-A | Pyrrolo [2, 3-d ] pyrimidine compounds | PFIZER PROD INC (US) | 2001-07-25 | — | — | CN | claimed |
| US-7687507-B2 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20050171128-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC | 2005-08-04 | — | — | US | disclosed |
| US-6890929-B2 | Immunosuppressants; lupus, multiple sclerosis, skin disorders, antiarthritic agents, antihistamines, antiulcer agents, Crohn's disease | PFIZER, INC. (US) | 2005-05-10 | — | — | US | disclosed |
| EP-1087970-B1 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PROD INC (US) | 2004-04-28 | — | — | EP | disclosed |
| CN-1128800-C | Pyrolo [2,3-d] pyrimidine compounds | PFIZER PROD INC (US) | 2003-11-26 | — | — | CN | disclosed |
| US-20030212273-A1 | Pyrrolo [2,3-D] pyrimidine compounds | PFIZER INC. | 2003-11-13 | — | — | US | disclosed |
| US-6610847-B2 | Tyrosine kinase inhibitors; immunosuppressants | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020019526-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2002-02-14 | — | — | US | disclosed |
| CN-1305480-A | Pyrrolo [2, 3-d ] pyrimidine compounds | PFIZER PROD INC (US) | 2001-07-25 | — | — | CN | disclosed |
| EP-1087970-A1 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065908-A1 | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019526-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK1, JAK3, JAK2 | JAK3 2/4885LCK 4/4885AKT2 731/4885 |
| US-20050171128-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK3, JAK1, JAK2 | JAK3 1/4885LCK 5/4885AKT2 950/4885 |
| US-20030212273-A1 | Pyrrolo [2,3-D] pyrimidine compounds | JAK1, JAK3, JAK2 | JAK3 2/4885LCK 4/4885AKT2 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.